CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Semaglutide Injectable Product +1 moredrug
Likely dose
Semaglutide: 0.25 mg weekly for 4 weeks, then 0.5 mg weekly for 4 weeks, then 1.0 mg weekly for 12 weeks (total 20 weeks)AI-extracted
Key inclusion· 4
  • ✓Age older than 65 years
  • ✓Prediabetes or type 2 diabetes
  • ✓BMI ≥27.0 kg/m²
  • ✓Living independently (not in assisted living or nursing home)
Key exclusion· 3
  • ✕Heart disease
  • ✕Liver disease
  • ✕Active smoking

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05786521
NCT05786521Phase 4Completed
CompareCT.gov

The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance

The University of Texas Health Science Center at San Antonio·interventional·Posted Mar 27, 2023·Updated May 4, 2025

In Brief

A Phase 4 clinical trial evaluating Semaglutide Injectable Product and Lifestyle Counseling for Aging and 3 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 4CompletedFinished
202420252026
First PostedMar 27, 2023
Enrollment StartApr 1, 2023
Primary CompletionMay 20, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.3 years ago

Interventions

Semaglutide Injectable Productdrug

Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.

Lifestyle Counselingbehavioral

Lifestyle Counseling will be provided throughout study intervention